Wednesday, July 8, 2026

Drug profile · INN

lucinactant

lucinactant (SURFAXIN) is a surfactant agent. Route of administration: intratracheal. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 10
News articles 0
Drug details — lucinactant
US status
approved
Class
Route
INTRATRACHEAL
Patents
0
Programs
10
Data quality
0.84

Quick answer

lucinactant (SURFAXIN) is a surfactant agent. Route of administration: intratracheal. Current US regulatory status: approved.

Key facts

INN lucinactant
Brand SURFAXIN
Mechanism Surfactant agent
Route INTRATRACHEAL
Formulation SUSPENSION

Mechanism of action

Surfactant agent

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. Lucinactant Phase 3 · WINDTREE THERAPEUTICS INC · Meconium Aspiration
  2. A.1 Lucinactant Phase 2 · WINDTREE THERAPEUTICS INC · Acute Respiratory Distress Syndrome
  3. Aerosolized lucinactant Phase 2 · WINDTREE THERAPEUTICS INC · Respiratory Distress Syndrome
  4. Lucinactant Phase 2 · WINDTREE THERAPEUTICS INC · COVID-19
  5. Lucinactant Phase 2 · WINDTREE THERAPEUTICS INC · Acute Hypoxemic Respiratory Failure
  6. Lucinactant 175 mg/kg Phase 2 · WINDTREE THERAPEUTICS INC · Respiratory Distress Syndrome, Newborn
  7. Lucinactant delivered via investigational delivery device Phase 2 · WINDTREE THERAPEUTICS INC · Respiratory Distress Syndrome
  8. Lucinactant first Phase 2 · WINDTREE THERAPEUTICS INC · Cystic Fibrosis

Frequently asked questions

What is lucinactant?

lucinactant (SURFAXIN) is a surfactant agent. Route of administration: intratracheal. Current US regulatory status: approved.

What is the brand name for lucinactant?

SURFAXIN is a marketed brand name for lucinactant. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lucinactant?

lucinactant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.